Stemline Therapeutics Inc (STML) COO Sells $50,096.85 in Stock

Stemline Therapeutics Inc (NASDAQ:STML) COO Kenneth Hoberman sold 3,027 shares of the business’s stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $16.55, for a total transaction of $50,096.85. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Kenneth Hoberman also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Tuesday, February 27th, Kenneth Hoberman sold 11,026 shares of Stemline Therapeutics stock. The shares were sold at an average price of $17.43, for a total transaction of $192,183.18.
  • On Thursday, February 15th, Kenneth Hoberman sold 1,851 shares of Stemline Therapeutics stock. The shares were sold at an average price of $15.67, for a total transaction of $29,005.17.
  • On Monday, January 8th, Kenneth Hoberman sold 14,040 shares of Stemline Therapeutics stock. The shares were sold at an average price of $13.93, for a total transaction of $195,577.20.
  • On Friday, December 15th, Kenneth Hoberman sold 11,943 shares of Stemline Therapeutics stock. The shares were sold at an average price of $14.18, for a total transaction of $169,351.74.
  • On Monday, December 18th, Kenneth Hoberman sold 11,983 shares of Stemline Therapeutics stock. The shares were sold at an average price of $14.18, for a total transaction of $169,918.94.

Stemline Therapeutics Inc (NASDAQ STML) opened at $18.50 on Friday. The stock has a market cap of $535.98, a PE ratio of -7.20 and a beta of -0.07. Stemline Therapeutics Inc has a one year low of $7.30 and a one year high of $18.50.

A number of research analysts have issued reports on STML shares. BidaskClub lowered shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 22nd. HC Wainwright set a $38.00 target price on shares of Stemline Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 14th. Zacks Investment Research raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, January 5th. Finally, ValuEngine raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $33.75.

A number of institutional investors have recently bought and sold shares of the business. Consonance Capital Management LP lifted its stake in shares of Stemline Therapeutics by 2,216.9% in the 4th quarter. Consonance Capital Management LP now owns 2,349,792 shares of the biopharmaceutical company’s stock worth $36,657,000 after acquiring an additional 2,248,372 shares during the period. BlackRock Inc. lifted its stake in shares of Stemline Therapeutics by 6.3% in the 4th quarter. BlackRock Inc. now owns 1,406,181 shares of the biopharmaceutical company’s stock worth $21,936,000 after acquiring an additional 83,044 shares during the period. Vanguard Group Inc. lifted its stake in shares of Stemline Therapeutics by 4.7% in the 2nd quarter. Vanguard Group Inc. now owns 863,768 shares of the biopharmaceutical company’s stock worth $7,946,000 after acquiring an additional 38,615 shares during the period. Lyon Street Capital LLC lifted its stake in shares of Stemline Therapeutics by 53.1% in the 4th quarter. Lyon Street Capital LLC now owns 829,090 shares of the biopharmaceutical company’s stock worth $12,934,000 after acquiring an additional 287,628 shares during the period. Finally, State Street Corp lifted its stake in shares of Stemline Therapeutics by 11.3% in the 2nd quarter. State Street Corp now owns 345,363 shares of the biopharmaceutical company’s stock worth $3,179,000 after acquiring an additional 35,116 shares during the period. 50.39% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2018/03/10/stemline-therapeutics-inc-stml-coo-sells-50096-85-in-stock.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply